No growth in revenue compared to H2 2021. Soaring expenses. Continued failure to execute on new products. Existing product runway facing imminent patent expiry. Incredibly overvalued.
No growth in revenue compared to H2 2021. Soaring expenses....
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NAN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.56 |
Change
0.120(3.49%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| $3.45 | $3.58 | $3.43 | $8.984M | 2.539M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 105140 | $3.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.56 | 6342 | 5 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| NAN (ASX) Chart |